Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron (Nasdaq: GERN) granted a 2,500,000-share stock option to Timothy Williams as an inducement for joining as Executive Vice President, Chief Legal Officer and Corporate Secretary.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) granted a 2,500,000-share stock option to Timothy Williams as an inducement for joining as Executive Vice President, Chief Legal Officer and Corporate Secretary.
The option was granted April 13, 2026, has a $1.73 exercise price (equal to the grant-date close), a 10-year term and vests over four years with 12.5% vesting at six months.
Positive
- 2,500,000-share option granted to new executive
- Exercise price set at $1.73, equal to grant-date closing price
- 10-year option term
- Vesting schedule: 12.5% at six months, remainder over following 42 months
Negative
- None.
Details
News Market Reaction – GERN
On Apr 15, the first trading day after this news, GERN closed 4.52% below the previous close.
Data tracked by StockTitan Argus for the Apr 15 session.
Key Figures
- Inducement option size
- 2,500,000 shares
- Stock option to new EVP, Chief Legal Officer
- Exercise price
- $1.73 per share
- Equals closing price on April 13, 2026 grant date
- Option term
- 10 years
- Term of inducement stock option grant
- Initial vesting tranche
- 12.5% of shares
- Vest on six-month employment anniversary
- Remaining vesting period
- 42 months
- Equal installments after initial six-month vest
Historical Context
-
Announcement of participation in the Needham Virtual Healthcare Conference.
-
New directors added to support commercial strategy for RYTELO.
-
Inducement stock options totaling 956,250 shares to new hires.
-
Q4 and full-year 2025 results with RYTELO revenue and 2026 guidance.
-
Planned management presentations at multiple March investor events.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock option financial
exercise price financial
vests over four years financial
inducement award plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron’s new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron.
The stock option was granted on April 13, 2026. The stock option has an exercise price of
The stock option grant was approved by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under that plan.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.